In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation-Reference-Cited by-同舟云学术

In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation

Published:2006-12 Issue:1-3 Volume:553 Page:229-239
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Lu Hua Rong,Vlaminckx Eddy,Van de Water Andre,Rohrbacher Jutta,Hermans An,Gallacher David J.

Publisher

Elsevier BV

Subject

Pharmacology

Reference37 articles.

1. Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarization in rabbit Purkinje fibers;Adamantidis;Fundam. Clin. Pharmacol.,1998

2. Effects of fluoroquinolones on HERG currents;Bischoff;Eur. J. Pharmacol.,2000

3. Pharmacokinetics of the ketolide telithromycin after single and repeated doses in patients with hepatic impairment;Cantalloube;Int. J. Antimicrob. Agents,2003

4. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome;Chen;Br. J. Pharmacol.,2005

5. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential?;Carlsson;J. Pharmacol. Exp. Ther.,1997

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug-Induced QT Prolongation;Reference Module in Biomedical Sciences;2024

2. Multi-algorithm based machine learning and structural pattern studies for hERG ion channel blockers mediated cardiotoxicity prediction;Chemometrics and Intelligent Laboratory Systems;2021-01

3. Utility of Normalized TdP Score System in Drug Proarrhythmic Potential Assessment: A Blinded in vitro Study of CiPA Drugs;Clinical Pharmacology & Therapeutics;2020-12-29

4. Sex: A change in our guidelines to authors to ensure that this is no longer an ignored experimental variable;British Journal of Pharmacology;2019-08-23

5. Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin;The AAPS Journal;2018-03-14